Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) President Chris Naprawa addresses the company’s recent stock volatility. Naprawa clears up a misconception created when the company announced it had signed a definitive agreement for the acquisition of NettaGrowth International. Naprawa explains the move was originally disclosed on January 25 and that the confusion stemmed from Khiron commencing US press releases with the announcement of the definitive agreement. Naprawa discusses the rapid evolution of the Latin American cannabis market and Khiron’s monitoring of changing regulatory frameworks. While Khiron is often grouped with domestic cultivators, it is more accurately described as a multi-jurisdiction medical and CPG company, according to Naprawa. Khiron is a leader in the emerging cannabis cosmeceutical space and Naprawa anticipates that the company’s CBD cosmetic products will be available in up to 400 stores in Colombia by the end of this quarter. Naprawa discusses the possibility of Kuida products being available in the US by the end of the year, as a result of Khiron’s JV with US-based Dixie Brands Inc (CNSX:DIXI.U) (OTCMKTS:DXBRF) (FRA:0QV) . ************************
Check out our website:
************************
SUBSCRIBE to our YouTube:
SUBSCRIBE to our 2nd YouTube Channel - Midas Letter Clips:
SUBSCRIBE to our Newsletter:
Download Our Podcast on iTunes:
************************
Follow Us on Twitter:
Like Us on Instagram:
Like Us on Facebook:
************************
#WeedStocks
#MidasLetter
0 Comments